Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Venous Thromboembolism 1Thrombosis 1Thrombophilia 1Thromboembolism 1Small Cell Lung Carcinoma 1Sarcoma 1Pulmonary Embolism 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Esophageal Neoplasms 1Digestive System Diseases 1

Interventions

Cisplatin 109Radiotherapy 100Fluorouracil 90Paclitaxel 75Oxaliplatin 63Docetaxel 56Carboplatin 55Irinotecan 41Esophagectomy 41Leucovorin 40Capecitabine 39Radiation 36Surgical Procedures, Operative 35Drug Therapy 31Neoadjuvant Therapy 25Chemoradiotherapy 18Cetuximab 18S 1 (combination) 17pembrolizumab 16camrelizumab 16Nivolumab 15Magnetic Resonance Spectroscopy 15Bevacizumab 15Blood Specimen Collection 14Surveys and Questionnaires 12Radiotherapy, Intensity-Modulated 12Immunotherapy 11Epirubicin 11Biopsy 11Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Neoplasms × enoxaparin sodium × Clear all
NCT03254511 2017-08-22

Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

Mashhad University of Medical Sciences

Phase 2 Unknown
100 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡